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{57] ABSTRACT
Methods of monitoring and detecting the early onset of
organ injury incident rejection of a organ rejection in an
animal are disclosed. The described methods are capable of
distinguishing organ rejection injury from other organ tissue
damagein the animal. Free secretory componentlevels in an
animal biological fluid (e.g., bile, urine, blood, amniotic
fluid) may be used to identify organ rejection in an animal.
Multiple and single organ transplant patients may be moni-
tored and diagnosed according to the claimed methods.
Biological fluids, such as blood, (serum) or urine, are
analyzed immunologically using a particularly adapted
ELISA which are then compared to an FSC control concen-
tration to identify elevated FSC values. Animals with test
FSC above FSC control concentrations are diagnosed as
having an ongoing organ rejection episode. The detection of
congenital renal dysfunction in utero is also provided
according to the present invention through the measurement
of FSC in the amniotic fluid. The described methods are
specific for indicating organ rejection tissue injury, and
distinguish kidney rejection tissue injury, in particular, from
other causes of kidney injury, such as cyclosporin toxicity,
urinary tract infection, and urinary obstruction and toxicity
(incident to immunosuppressive therapy with cyclosporin).
A kit for use in the identification of an organ rejection
episode in a patient through measurement of FSC in a
biological sample is also provided.
17 Claims, 2 Drawing Sheets
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ASSAY FOR FREE SECRETORY
COMPONENT AND METHODS FOR
MONITORING ORGAN REJECTION
The United States Government may have rights in the
present invention as relevant developmental work was sup-
ported by a National Institutes of Health (NIAID) RO1
Grant No. AJ21412 and pursuant to a contact with NICHD
(#6-918) HD 62918. This is a continuation of application
Ser. No. 07/736,448filed Jul. 26,1991 and now U.S. Pat No.
5,340,721.
BACKGROUNDOF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of
diagnostic medicine, most particularly, to the field of meth-
ods for diagnosing organ graft rejection. The invention
telates to methods for monitoring and detecting organ rejec-
tion in a patient through immunodiagnostic assays which
measure free secretory component (FSC) in a biological
sample.
In that particular embodiments of the present invention
relate to the measurement of FSC in a urine sample,the field
of the present invention also relates to urine sample analysis
for the detection of organ rejection. In most preferred
embodiments of the described invention, a method[ for
monitoring and detecting allograft rejection is provided
through the monitoring of urine concentrations of the gly-
coprotein free secretory component. The described inven-
tion most particularly relates to the field of methods for
detecting renal allograft rejection, as the procedures dis-
closed herein are capable of distinguishing renal allograft
rejection from other form; of renal and extra renal problems
in kidney transplant patients.
The present invention also relates to the field of diagnostic
assay kits, as a diagnostic kit for use in the screening of
kidney transplant patients to detect early kidney rejection is
provided.
2. Description of the Related Art
Approximately 10,000 kidney transplants are performed
annually in the United States. Despite the availability of
potent immunosuppressive agents, graft rejection remains
the main complication of renal transplantation. For example,
approximately 50% of all renal allograft recipients are
thought to suffer at least one episode of graft rejection. The
likelihood of kidney loss due to rejection is highest during
the first year post transplant (10-20%), but a small propor-
tion| (3-5%) of kidneys are rejected each year even after
that’.
The statistics indicate that graft rejection is often not
detected early enough in the rejection episode to allow
initiation of countervailing treatment, which would effec-
tively halt the rejection process, in time to prevent the organ
rejection. A method for the early detection of graft rejection
would thus be an importantclinical tool for maintaining the
viability of a transplanted organ through early detection in
the rejection process. The clinician would thus be provided
an opportunity to administer immunosuppressive agents to
the patient at a time when the rejection process could be
effectively halted and/or prevented altogether.
The diagnosis of acute allograft rejection is classically
based on the presence of one or more symptoms. For
example, symptoms of acute allograft rejection include
weight gain, reduced urine output, increased serum creatine
concentrations, hypertension, fever, and graft enlargement
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and tenderness. However, the use of these symptomsalone
to detect rejection is not adequate. Currently, most transplant
rejection episodes are detected by measuring periodically
the function of the transplanted kidney, for example by using
biochemical tests such as assays which measure serum
creatine concentrations alone.
Other non-invasive methods for detecting renal graft
rejection are under investigation, and depend primarily on
the measurementof“indicators” of activation of the immune
system. For example, the quantification of T-lymphocyte
subsets” or soluble T-cell surface receptors (e.g., interleukin
2 receptor)® in the blood have been used to monitor graft
rejection.
Unfortunately, other complications of the transplant pro-
cedure, including urinary tract infection, urinary obstruction
and toxicity of the immunosuppressive therapy itself (par-
ticularly with cyclosporin A), often mimicthe clinical and/or
laboratory findings of graft rejection. For example, kidney
toxicity to cyclosporin A (a drug used to prevent rejection of
kidneys) often results in elevated levels of creatinine in the
serum and adenosine deaminase binding protein in urine.
The measurement of these constituents would therefore fail
to distinguish kidney rejection per se from toxicity to the
immunosuppressive agents used to prevent rejection. Such
would render false positive results for graft rejection in a
patient. In addition, other unrelated illnesses can produce
clinical and laboratory findings which resemble those of
renal transplant rejection. For instance, T-cell activation may
occur during common viral infections as well as ,during
episodes ofrenal allograft rejection*, again lending to the
occurrence of false positive laboratory results in a patient.
In addition, many abnormalities of the kidney are
reflected in changes in the volume and composition of the
urine. Therefore, urine tests might provide a more direct and
therefore specific, indication of renal allograft rejection than
assays for components included in the blood. Measurement
of renal tubular and serum proteins in the urine, including
B-2 microglobulin®°, gamma glutamyl trans-peptidase®,
N-acetyl-B-D-glucosaminidase”®, adenosine deaminase-
binding protein’®’! (produced by proximal nephron),
complement components, and lysozyme*” have all been
proposed. However, none of these markers have been shown
to distinguish the injury from renal allograft rejection apart
from other renal injuries.
Presently, renal biopsy remains the most definitive test to
specifically diagnose renal allograft rejection. However, this
method has major limitations. For example, since the biopsy
procedureitself has complications, and since a portion of the
renal transplant is removed during each biopsy, transplant
biopsy cannot be performed on a routine or even frequent
basis to monitor renal allograft rejection. In addition, the
invasive nature of a renal biopsy is both uncomfortable and
inconvenient for patient subjects. Accurate interpretation of
the renal transplant biopsy also demandsthe expertise of a
pathologist with extensive experience in analyzing a biopsy
sample for evidence of renal transplant rejection. Hence,
renal biopsies are reserved for those patients that demon-
strate other clinical and/or laboratory evidence of renal
allograft rejection limiting its use or potential use in detect-
ing early graft rejection.
While no direct evidence for the induction of secretory
component in kidney cells by injury is knownto exist, one
immunohistologic study of renal autopsy tissue demon-
strated that secretory component was much more prominent
in the distal tubules when renal disease was present”®. The
present inventors have recently examined a representative
5,484,707
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number of biopsies from renal allografts from patients
undergoing graft rejection, and compared these to biopsies
from patients with cyclosporin toxicity, using immunofluo-
rescence assays with monoclonal antibodies to secretory
component. From these preliminary observations, the inven-
tors found that kidneys undergoing rejection expressed
much more secretory component in their distal tubules
compared to kidneys from patients with cyclosporin toxicity
(unpublished data). The inventors therefore propose a never-
before-described method for discerning kidney rejection in
patients receiving immunosuppressive agents such as CSA,
by monitoring urinary free secretory component. Concen-
trations of FSC are not observed to increase with the
administration of immunosuppressive drugs (or reactions
thereto), thereby essentially eliminating false positive results
for kidney rejection.
Secretory componentis an 80,000 molecular weight frag-
ment of an integral (trans) membrane glycoprotein, termed
“polymeric immunoglobulin receptor” (PIgR). PigR is syn-
thesized by secretory epithelial cells which line the mucosal
surfaces of the body!”!%. It mediates binding, endocytosis
and vectorial transport of polymeric IgA (pIgA), and to a
lesser extent IgM"*, from the basal lateral to the apical
surface of the epithelial cell’*'°. Here, the PIgR is pro-
teolytically cleaved near the outside surface of the epithelial
cell?releasing the N-terminal segment, termed secretory
component(SC).
The secreted secretory component, complexed with plgA,
is termed “secretory IgA” (slgA)'*. In this complex, secre-
tory component is thought to protect the IgA from pro-
teolytic cleavage. The large amounts of sIgA foundin saliva
and gastrointestinal secretions, lung secretions, cervicovagi-
nal secretions, breast milk, and tears are thought to consti-
tute the first line of immunological defense against some
mucosal infections. The smaller amount of sIgA found in ~
urine mayalso help protect against urinary tract infection”.
Whensecretory component is secreted from the epithelial
cell without any immunoglobulin attached, it is termed
free-secretory component (FSC). FSC has also been
reported in all external secretions in smaller amounts*. The
exact function of FSC remains unknown.It is hypothesized
that the synthesis of secretory component in some tissues
may be regulated by hormones”*and other soluble media-
tors, such as cytokines involved in inflammation.In cultured
colon carcinoma cells, the cytokines interferon gama and
tumornecrosis-o and interleukin-4, alone and in combina-
tion, have been shownto increase the production and releaseof secretory component.?5-27
The term “secretory component”, as used in describing
the present invention, refers to either the conjugated (sIgA-
associated) or unconjugated (FSC) form of the secretory
component molecule. Free secretory component (FSC), as
used in describing the present invention, refers only to the
free, unconjugated form of the secretory component mol-
ecule.
Since secretory component is normally secreted from the
luminal surface of epithelial cells, the inventors hypothesize
that it is likely that increased production of secretory com-
ponentin the kidney will increase excretion of slgA and/or
secretory componentin the urine. A recent study quantified
slgA by ELISAin the urine ofpatients with a variety ofrenal
disorders”?. Comparedto healthy subjects, patients with IgA
nephritis and other forms of chronic glomerulonephritis had
elevated urinary sIgA. Urinary sIgA levels were only
slightly increased in heavy proteinuria. Additionally, the
highest concentrations of urinary sIgA (22-fold above nor-
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mal) were found in patients with urinary tract infections.
Renal allograft recipients with stable graft function had
urinary sIgA levels that were only slightly increased above
those of normal individuals. These results suggest that
urinary sIgA production is enhanced by renal inflammation,
perhaps due to induction of local secretory component
and/or IgA production.
Urinary free secretory component (FSC) excretion,
(unconjugated secretory component) hasnot been studied as
extensively. As will be recalled, FSC (or free secretory
component) is produced by the distal nephron. It has been
observed that the level of expression and excretion of FSC
may be increased by renal inflammatory reactions like
infection”® orallograft rejection, as well as by tubular injury.
One recent study demonstrated that urinary FSC did not
differ between persons with acute/recurrent urinary tractinfections, and normal controls.°? Nor did urinary FSC
levels differ between patients with IgA deficiency and age
and sex-matched normal adult control subjects.>7
A major characteristic of the secretions that protect
mucosal surfaces is that they contain products of the poly-
meric immunoglobulin transport system, namely secretory
immunoglobulins (sIgA and sIgM)and free secretory com-
ponent (SC). SC expression has even been demonstrated as
presentin fetal tissues. For example, by the seventh week of
gestation, even before the fetus is able to produce Ig, SC has
been detected in fetal tissues. Free SC (free secretory
component) has been observed by the inventors in human
amniotic fluid. Based on reactivity with antisera to secretory
component, the IgA of amniotic fluid is thought to be sIgA
. immunoglobulin containing secretory component®?.
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Amniotic fluid is known to serve as an immunological
barrier between the fetus and maternal external environ-
ments, thereby protecting against intrauterine infections. As
already noted, amniotic fluid has been reported to contain
low levels of sIgA and other proteins typical of external
secretions, but these proteins are not usually considered. an
immunologic secretion*. Thus, the role and sourcesof the
various forms of secretory component (SC) in amniotic fluid
have not yet been completely characterized.
The present inventors have foundthat the concentration of
SC in amniotic fluid (AmF) varies with the gestational age
of the fetus. Additionally, the inventors have found that most
of the SC in humanAmF existsin its free form (FSC). In this
regard, the inventors observed that amniotic: fluid from full
term pregnancies contained FSC in concentrations compa-
rable to other external secretions, such as saliva or bile*.
The fetal urogenital system and the amniotic membrane
have been demonstrated to contribute to FSC levels and
sIgA levels in amniotic fluid. Given those observations
already collected by the inventors and others regarding FSC
and SC in fetal tissues and AmF, the inventors propose a
method for monitoring fetal kidney abnormalities through
monitoring fetal secretory component levels in amniotic
fluid. For example, this proposed method may be used to
monitor the disease knownas Potter’s Syndrome(a disorder
characterized by abnormal fetal kidney development).
Detection of kidney malfunction early in pregnancy by
monitoring AmF levels of FSC would provide an extremely
valuable diagnostic tool for following fetal kidney develop-
ment. Once detected, the kidney-malfunctioning fetus might
be treatable by the clinician and alert the patient to the
condition.
A simple, non-invasive method for rapid detection of
kidney and other organ rejection episodes would have the
dual advantage of requiring no venipuncture or biopsy and
5,484,707
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further allowing testing at virtually any clinic or office
temote from actual transplantation medical centers. More
specifically, a urinary FSC test to monitor kidney rejection
as a screening procedure would have practical utility as an
initial non-invasive procedure that would quickly alert the
physician of the need for further, more extensive and/or
patient involved evaluation and treatment. Quantification of
urinary FSC may also be useful in distinguishing inflam-
matory renal disease (rejection or infection) from renal
toxicity precipitated from immunosuppressive drugs, such
as cyclosporin A.
A simple, non-invasive diagnostic test which could serve
as an initial screening procedure for detecting renal trans-
plant rejection, or could distinguish rejection from other
diseases that produce the same symptoms and biochemical
changes, could improve greatly the prognosis of patient
kidney transplant recipients. As allograft rejection can often
be treated effectively if detected early, the availability of an
effective screening test for early graft rejection detection
which could be performed conveniently on a relatively
frequent periodic basis would potentially improve the sur-
vival of both the transplanted organ, and the transplant
patient. Ultimately, such a test could also reduce the high
cost of treating chronic renal failure.
SUMMARYOF THE INVENTION
The present invention provides a simple, rapid and spe-
cific method for monitoring and/or identifying organ rejec-
tion in an animal. It is contemplated that the present methods
may be advantageously employed in the detection of both
single organ rejection as well as multiple-organ rejection
(such as the liver, kidney, lung or pancreas or any combi-
nation thereof) in a transplant patient. The most preferred
application of the described methodsrelate to the detection
and monitoring of the rejection of kidney allografts in an
animal.
Allograft, as that term is used in the present application,
refers to an organ which is transplanted into an animal of the
same species as the organ donor. The described methods
alert of an ongoing organ rejection episode through the
detection of an elevated or otherwise abnormal concentra-
tion of free secretory componentin a biological sample from
the animal. The detection of elevated free secretory com-
ponentlevels in the animal above concentrations character-
istic of a defined “control” FSC concentration of a like-
biological fluid, such as from a transplanted animal without
previous episodesof graft rejection, will identify an ongoing
organ rejection in the animal.
Even more particularly, the present invention provides
methods whereby renal tubular inflammation, specifically
the tubular inflammation attendant renal allograft rejection,
is determined based on quantification of the glycoprotein
free secretory component (FSC,also termed free secretory
component of IgA and polymeric immunogobulin receptor)
in the voided urine of renal allograft recipients.
The diagnostic value in monitoring human renal trans-
plant patients by the measurement of FSC concentrationsis
indicated by data generated by the inventors which shows
that FSC concentration in urine is greater in patients admit-
ted to a renal transplantation unit for suspected graft rejec-
tion than in non-renal transplant control patients. The con-
centration of urine FSC also has been demonstrated to fall
rapidly in some patients after their medicinal regimen has
been changed. This indicates to the present inventors that
urine FSC measurements may also be used as a signal of
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whena changein treatmentis reversing rejection of a grafted
organ.
The present invention most particularly provides a non-
invasive method for identifying organ injury incident to
organ rejection in an animal, the method comprising first
obtaining a biological sample from the animal having an
organ transplant; measuring a concentration of FSC in the
biological sample to provide an FSC test concentration;
comparing the FSC test concentration to a control FSC
concentration characteristic for the biological sample; and
identifying an organ injury incident to organ rejection in an
animal having an FSC concentration greater than the FSC
control concentration.
Most preferably the biological sample used to determine
the control FSC value should be the same type ofbiological
sample obtained from the “test” animal. For example, where
the animal sample obtained is a urine sample, a reference
control value of FSC should be determined from a urine
sample obtained from an animal(s) having had an organ
transplant with no prior known episodes of organ rejection,
from an animal(s) with no organ transplant or from an
autologous urine sample obtained from the animal prior to
any incidence of any organ rejection episode.
The present inventors have found that FSC concentrations
will vary as between types of biological fluids/secretions,
such as urine, bile, bronchial secretions, milk, serum and
amniotic fluid. Any one of these biological fluids may be
used for the purpose of measuring FSC concentration. Most
preferably, the biological fluid for test and control FSC
determinations is urine. Most preferably, in both the method
for inhibiting a kidney transplant rejection, identifying a
renal allograft rejection episode and for distinguishing renal
allograft rejection injury from renal non-allograft injury in a
kidney transplant recipient, the FSC control concentration
and FSC test concentrations are normalized as against the
creatinine concentration of the biological sample.
A control FSC concentration of a biological sample may
be determined from an autologous biological sample
obtained from the patientprior to any evidence or incidence
of an organ rejection episode. Alternatively, the control free
secretory component concentration may be determinedas an
average of a representative number of like-biological
samples obtained from a control population of animals. The
control reference population may comprise a representative
numberof non-transplant animals, or a representative num-
ber of animals having had an organ transplant of the same
organ as the animal under observation with no prior episodes
of organ rejection.
The present invention is expected to provide a noninva-
sive and economical method for frequently monitoring the
efficacy of a transplant recipients immunosuppression
therapy regimen, as well as for monitoring the status of an
organ (e.g. kidney) transplant in the transplant recipient. The
tejection/monitoring of a numberof different organs may be
accomplished, using the described noninvasive method. By
way of example, organs which may be monitored according
to the methods described herein include a liver, kidney, lung
or pancreas grafted organ ortissue. In a preferred embodi-
ment, the described methods are employed to monitor/detect
kidney organ rejection in a human.
The ability to provide early detection of ongoing trans-
planted organ rejection episode will facilitate early patient
treatment, enhancing the success of preventing incipient
transplant rejection. The increasing shortage of organsavail-
able for transplant, and the difficulties associated with
obtaining an initial histocompatible organ-donor, highlight
5,484,707
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the important feature of the claimed invention for improving
the success rate of organ transplant as a treatment. Thus,
organ rejection as a majorrisk associated with organ trans-
plant, and may be virtually eliminated through early detec-
tion and subsequent prompt and effective immunosuppres-
sive clinical intervention employing the methods of the
present invention.
Measurement of FSC in a urine sample as a method to
identify or inhibit an ongoing renal allograft rejection epi-
sode, in particular, has not to the inventors knowledge been
reportedin the literature. Various components in urine, such
as renal, tubular and serum proteins, including the B-2-
microglobulin,>° y-glutamy]trans-peptidase’, N-acetyl-B-d-
glucoseaminadase*” adenosine deaminase binding protein’!and complement component and lysozyme’® have been
measured. However, none of these substances have been
shown to distinguish renal allograft rejection from other
forms of extra-renal or kidney injury (e.g., cyclosporin
toxicity).
A method for distinguishing renal injury resulting from
allograft rejection and other forms of renal injury is an
important further feature of the claimed invention, since
increasing a patient’s immunosuppressive therapy inappro-
priately can worsen other conditions attendant the specific
renal injury, and further increase other complications atten-
dant the therapy.
The present invention provides a method whereby an
ongoing organ rejection episode may be determined by
immunological analysis of any of a variety of biological
fluids, including urine, bile, amniotic fluid, and bronchial
secretions, serum as well as otherbiological fluid secretions.
Mostpreferably, the present methods may be used in con-
junction with a urine sample (in the case of testing for
kidney injury the result of allograft organ rejection). In a
second most preferred embodiment, the presently disclosed
methods may be used in conjunction with amniotic fluid (in
the case of a diagnostic test for fetal renal dysfunction).
As a method for inhibiting kidney transplant rejection in
an animal with a kidney transplant, the method comprises
the steps offirst obtaining a urine sample from the animal at
periodic intervals after the kidney is transplanted, measuring
FSC concentrations in each urine sample of the animal to
provide test sample FSC concentrations; determining a
control FSC urine concentration; identifying an elevated
FSC test concentration in a test sample having an FSC
concentration greater than the control FSC urine concentra-
tion; classifying an animal having an elevated concentration
of FSC as undergoing a kidney rejection episode; and
treating the animal undergoing a kidney rejection episode
with a regimen of immunosuppressive agents to inhibit
kidney transplant rejection in the animal.
Acontrol free secretory component concentration may be
determined from a control reference population which may
comprise a group of organ transplantrecipients with no prior
history of episodes of organ rejection or from non-transplant
patients of similar age and sex.
As a method for identifying a renal allograft rejection
episode in a kidney transplantpatient, the present invention
in a particularly preferred embodiment comprises first
obtaining a patient urine sample from the transplantpatient,
determining the FSC concentration in the patient urine
sample to provide an FSC test concentration; determining an
FSC urine concentration from urine samples of non-kidney
transplantpatients to provide an FSC control concentration;
comparing the FSC test sample concentration to the FSC
control concentration; and identifying a renal allograft rejec-
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tion episode in the kidney transplant patient when an FSC
test concentration is greater than the FSC control concen-
tration. While the concentration of FSC in the biological
sample may be determined by several methods, the most
preferred method for measuring the concentration of FSC in
a urine sample, for example, is by an enzymelinked immu-
nosorbent assay (ELISA).
An immunological method most preferred for use in the
present invention for the measurement of free secretory
component (FSC) in virtually any biological fluid is the
ELISA (enzyme linked immunosorbent assay), which has
been modified in particular aspects for the purposes of the
present invention. One feature of the modified ELISA
includes the capability of measuring FSC at extremely low
concentrations in a biological sample (5 ug/ml).
Identification of a potentially pathologic concentration of
FSC is determined on the basis of a comparative testing
scale, wherein the test sample FSC concentration is judged
to be “elevated” or “normal” as against a baseline control
concentration value characteristic of the particular biologi-
cal fluid being measured. For example, where the biological
fluid is a human adult male voided urine sample, the
characteristic baseline control concentration of FSC is about
1 pg/ml. This value was calculated as a mean FSC value of
15 non-kidney transplant voided urine samples from adult
male human subjects. In contrast, the mean urine FSC
concentration value for 15 kidney transplant patients having
a history of at least one episode of renal rejection was
determined to be about 25 pg/ml.
A characteristic baseline FSC control value may be
derived from either an autologous, pre-rejection episode
biological sample level, or from a control population of
biological samples, such as from a representative number of
non-transplant patient samples, or a representative number
of transplant patient samples from patients who had received
a transplanted organ but who had not demonstrated any
previous episodes indicating organ rejection.
Identification of a potentially pathogenic organ rejection
episode may also be madeonthebasis of relative levels of
FSC/creatinine in the test sample compared to controls. An
average FSC/creatinine ratio, as determined from a control
population of urine samples from non-transplant adult
human patients, was about 1.04 ug FSC/mgcreatinine, the
range being between 0.19-3.38 ig FSC/mgcreatinine (Table
3). A normal FSC/creatinine range of between 0.32-2.5 pg
FSC/mg creatinine was therefore determined for non-trans-
plant, control patient urine samples. In contrast, the range for
FSC creatinine in renal transplant patients who had no
biopsy evidenceofrenal allograft rejection is about N.D.—26
ug FSC/mg creatinine (N.D.=non-detectable levels with
ELISA assay). Two of 5 patients had some FSC/creatinine
values greater than 2.5 yg/mg creatinine. However, 6
patients with renal biopsy evidence of kidney rejection had
a range of N.D.-94 yg FSC/mgcreatinine. All 6 of these
patients had values greater than 2.5 ug/mg creatinine during
their hospitalization.
The presently disclosed methods are also exquisitely
specific for distinguishing kidney injury from allograft rejec-
tion from other non-allograft kidney damage. Thus, a
method for distinguishing renal allograft rejection kidney
injury from non-allograft kidney injury in a kidney trans-
plant patient is provided as one particularly preferred
embodiment of the claimed invention. As a method for
distinguishing renal allograft rejection from non-allograft
kidney injury in a kidney transplant patient, the method
comprisesthe stepsoffirst obtaining a urine sample from the
5,484,707
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kidney transplant patient with a form of kidney injury,
determining a FSC concentration in the patient urine sample
to provide an FSC test concentration, determining an FSC
control concentration from a urine sample obtained from a
reference control population having no prior history of renal
allograft rejection to provide a FSC control concentration;
and comparing the FSC test sample concentration to the FSC
control concentration; wherein an FSC test .concentration
greater than the FSC control concentration indicates a renal
allograft rejection in the kidney transplant patient and
wherein an FSC test concentration the same as or less than
the FSC control concentration indicates a non-allograft renal
injury.
A control or baseline urine free secretory component
(FSC) concentration may be determined as from any of the
described control populations(i.c., autologous pre-rejection
episode FSC biological sample concentration, or control
reference population FSC concentration from a non-trans-
plant population of biological samples or a population of
like-organ transplant recipients with no prior history of a
graft rejection episode).
In the above described method for distinguished organ
rejection kidney injury from other kidney injury, an animal
having a form ofkidney injury may be identified in a kidney
transplant patient having an elevated level of a marker
selected from the group consisting of: B-2 microglobulin;
gamma glutamyl trans-peptidase, N-acetyl-B-D-glu-
cosaminidase; adenosine deaminase-binding protein,
complement component; and lysozyme.
The present methods and techniques are also postulated to
constitute an effective method for monitoring graft-verses-
host disease. In particular, the measurement of FSC in a
bone-marrow transplant patient biological sample to detect
rejection of epithelial tissue is described herein. Accord-
ingly, a patient sample, most preferably a blood serum
sample, would first be obtained, and the concentration of
FSC therein determined and compared to an FSC control
concentration (measured from a control sample of serum).
Most preferably, the FSC control concentration is deter-
mined from serum samples obtained from patients who had
not received a bone marrow transplant.
Otherrenal conditions, including renal inflammation such
as renal infection, kidney rejection or renal tubular injury,
may be monitored through periodic measurement of an
animal’s urine FSC concentration. As a method for detecting
renal inflammation in an animal, the method comprises the
steps of obtaining a urine sample from the animal, deter-
mining the concentration of glycoprotein free secretory
component in the animal urine sample and comparing the
concentration of glycoprotein free secretory component in
the animal sample to a control concentration of free secre-
tory component, wherein a concentration of glycoprotein
free secretory component in the animal sample higher than
the control concentration of glycoprotein free secretory
component indicates renal inflammation in the patient. This
method is most particularly envisioned as suitable for detect-
ing renal allograft related inflammation in a human.
Disclosed also is a method for monitoring fetal renal
dysfunction. Such is to be accomplished by monitoring
amniotic fluid levels of FSC. Particularly, the condition
known as Potter’s Syndrome (a condition characterized by
the malformation of the fetal kidney) may be identified in the
fetus of a pregnant patient where the amniotic fluid FSC
concentration is diminished. A concentration of amniotic
fluid FSC less than a control concentration ofFSC from fluid
amniotic obtained from pregnancies of similar gestational
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ages, would be indicative of fetal renal dysfunction, most
particularly Potter’s Syndrome, in a human fetus. Again,
FSC levels are most preferably determined by a modified
ELISA, such as the assay described herein.
A kit for use in the detection of graft rejection is also
provided. The kit includes a carrier means adapted to receive
at least one multiwell assay plate andat least three container
means. One container means preferably includes a volume
of free secretory component, with a second container means
most preferably comprising an enzyme-conjugated antibody
having binding affinity (specificity) for free secretory com-
ponent antigen and a third container means comprising a
receptor ligand capture reagent. In a most preferred embodi-
mentof the kit, the antibody is a monoclonal antibody 6GI1
and the receptor ligand capture reagent is an anti-secretory
component antibody bound to an enzyme, such as polymeric
IgA or IgM conjugated to an enzyme, such as horseradish
peroxidase.
The kit may also optionally include a diluent solution with
a stabilizing ingredient. By way of example, such a diluent
may be a borate or phosphate buffered saline buffer. The
FSC employedin the present invention to be used in ELISA
assay (i.e., preparing a standard curve, etc) is most prefer-
ably FSC derived from human milk. One particular method
by which FSC may be derived from human milk is described
by Mach?*, which reference is specifically incorporated
herein by reference for this purpose.
The following abbreviations are used by inventors
throughout the description of the present invention:
ELISA=Enzyme linked immunosorbent assay
FSC=Free Secretory Component
IgA=Immunoglobulin A
N.D.=Non-detectable concentration of measured compo-
nents in a biological sample using an ELISA assay
SC=Secretory Component, conjugated or unconjugated
form
slgA=Secretory IgA; conjugated form of SC
AmF=Annniotic fluid
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1: Scatter Plot of free SC levels in amniotic fluid
during gestation. Amniotic fiuid samples taken at various
gestational ages were assayed for free SC content by quan-
titative ELISA. Points on the scatter plot represent the level
of free SC in individual samples.
FIG.2: Relationship between urinary FSC andcreatinine.
This regression analysis indicates the value of normalizing
the data as FSC/creatinine. This ratio is calculated so as to
increase the reliability and fidelity of the test results, as
much as the variability of the values are due to the charac-
teristic concentration level of the urine obtained from the
animal. The correlation coefficient for creatinine (r* for
creatinine vs. FSC) is 0.65.
DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS
The present invention provides for a surprisingly sensitive
method useful in the early detection of organ rejection
episodes in an animal. Particularly, the present methods are
based on the rapid and sensitive quantification of glycopro-
tein free secretory component (FSC,also termed “secretory
component of IgA”and “polymeric immunoglobulin recep-
tor’) in a biological sample. While this particular glycopro-
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tein may be measured in a variety of different biological
fluids, those biological fluids found most easily adaptable
for use in the present methods includedurine, amniotic fluid,
bile, bronchial secretions and serum. Most preferably, the
disclosed methods are used to measure FSC concentrations
in a urine sample obtained from the animal beingtested.
The present invention may be used to monitor and detect
rejection of a single organ, or even the rejection ofmore than
one organ, for example in patients who have received more
than one type of organ transplant. However, those applica-
tions of the invention most preferred are drawn to methods
for monitoring the rejection of a kidney transplant. By way
of example, the presently disclosed methods may also be
used to monitor liver, lung, pancreas or any combination
thereof, in an animal. In one most particularly preferred
embodiment, the method is used to monitor organ rejection
in a human patient.
In the described methodfor identifying organ rejection in
an animal, the method comprises the steps of obtaining a
biological sample from the animal; measuring a concentra-
tion of free secretory component in the biological sample;
comparing the concentration of free secretory component of
the biological sample to a standard free secretory component
concentration characteristic of a similar biological fluid. A
standard FSC concentration may be obtained from samples
obtained from non-organ transplant animals or from an
animal which had received an organ transplant demonstrat-
ing normal transplanted organ functioning or from a sample
obtained from the transplant animal (autologous) prior to a
episode of organ rejection. Identification of an ongoing
organ rejection, or the tissue damage which results from
organ rejection (causes organ rejection in an animal), is
determined in animals having a free secretary component
concentration greater than a determined standard control
free secretory component concentration characteristic of the
biological fluid being measured.
A standard concentration of free secretory component
concentration characteristic of a particular biological sample
is determined by calculating the mean and 95% confidence
interval ofFSC concentration obtained from, for example,at
least five age and sex-matched biological samples obtained
from animals which had not received an organ transplant.
Most preferably, where the animal being monitored is a
human, the reference population for determining control
values most preferably includes at least 10 age and sex-
matched animals. A 95% confidence interval is determined
from the FSC concentrations determined from biological
samples obtained from animals (for example, human sub-
jects) in the reference population.
Alternatively, the free secretory component concentration
characteristic of the biological sample to be used for com-
parative purposes may be the FSC concentration measured
in an autologous sample before any rejection episode had
occurred in the patient, or instead from an average FSC
concentration measured for the patient after a rejection
episode, but not during periods when the patient was expe-
riencing a rejection episode. Alternatively, a mean and 95%
confidence interval of FSC concentration may be calculated
from a group of biological samples obtained from animals
whohadreceived an organ transplant but who had noprior
evidence of an organ rejection episode.
Most preferably, the biological sample in which FSCis to
be measured is a urine sample.
FSC levels have been observed to decrease rapidly in
somerenal transplantpatients after their medicinal treatment
has been changed. Therefore, the present invention may also
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be used in a method to conveniently and economically
monitor a patient for the efficacy of an immunosuppressive
agent regimen, which would concurrently indicate the status
of the patients’ renal transplant.
The present invention also provides a method for inhib-
iting a kidney transplant rejection in an animal. In a par-
ticular embodiment of the present invention, this method
comprises the steps of obtaining a urine sample from the
animal at subsequent periodic intervals after the kidney is
transplanted; measuring free secretory component concen-
trations in each urine sample of the animal to provide test
sample FSC concentrations; determining if the free secretory
component concentration of the sample is elevated relative
to a control free secretory component concentration; classi-
fying an animal with an elevated concentration of urinary
free secretory component as undergoing a kidneyrejection
episode; and treating the animal undergoing a kidney rejec-
tion episode with a regimen of immunosuppressive agents to
prevent kidney rejection in the animal.
A similar method is provided in the present invention for
identifying a renal allograft rejection episode in a kidney
transplant patient. More specifically, the method for identi-
fying a renal allograft rejection episode in a kidney trans-
plant patient comprises: obtaining a patient urine sample
from the transplant patient; determining the concentration of
free secretory component in the patient urine sample to
provide an FSC test concentration; determining an FSC
urine control concentration from a population of at least 5
age and sex matched kidney transplant patients with no prior
evidence of a kidney rejection episode; comparing the FSC
urine control concentration to the FSC test concentration,
wherein an FSC test concentration greater than the FSC
concentration indicates a renal allograft rejection episode in
the kidney transplant patient.
Mostpreferably, a patient urine sample is to be obtained
before any signs of kidney rejection become evident. Addi-
tionally, frequent periodic urine specimens should be
obtained and FSC measured from the kidney transplant
patient as part of a comprehensive and effective monitoring
system for the early detection of kidney transplant rejection.
Where the biological sample is a human urine sample,the
control concentration of free secretory component in a
non-kidney transplant human is about 1 pg/ml. While a
variety of particular biochemical assays may be used to
measure free secretory component in a biological sample,
the assay most preferably used for this purpose is the
modified ELISA (enzyme linked immunosorbent assay)
described herein by the inventors (see Table 1).
Changes (i.e., an increase) in urine FSC levels are
expected to occur relatively early in the organ rejection
episode, and therefore the measurement of this particular
glycoprotein provides for early detection of an incipient
organ rejection episode, and further allows the physician to
timely interveneto halt the ultimate rejection of the organ.
Thespecificity of the claimed invention for monitoring
changes in the status of a transplanted kidney in an animal
provides a definitive technique for distinguishing renal
allograft rejection tissue injury from other forms of kidney
injury, such as that manifest from cyclosporin toxicity. Most
particularly this method comprises: obtaining a urine sample
from the transplant recipient animal; determining an FSC
concentration in the urine sample from the transplant recipi-
ent animal to provide an FSC test concentration; determin-
ing an FSC control concentration; and comparing the FSC
test concentration to the FSC control concentration of,
wherein an FSC test concentration greater than the. FSC
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control concentration indicates a renal allograft rejection
injury in the kidney transplant patient and wherein an FSC
test concentration the sameas or less than the FSC control
concentration indicates a renal non-allograft injury.
The presently disclosed novel approach to monitoring
organ rejection possesses the advantages of being economi-
cal, simple to administer, and noninvasive. The described
method also offers a much more patient compatible alterna-
tive to other techniques currently practiced. The present
methods also advantageously provide a method wherein
renal allograft rejection may be specifically distinguished
from other causes of kidney injury (e.g., cyclosporin toxic-
ity). The specificity of the present inventive methods are
thus unlike techniques which rely on biochemical measure-
ment of serum components to monitor renal function or the
excretion of other renal tubular and serum proteins ofurine,
including the B-2 microglobulin,y-glutamyl trans-peptidase,
acety!-B-D-glucose aminidase, adenosine deaminase bind-
ing protein, the complement components, and lysozyme.
Measurementof these substances do notdistinguish kidney
injury incident transplant rejection from other forms of
kidney injury.
In that the inventors have also characterized changes in
amniotic fluid content of FSC with the gestational age ofthe
fetus, the present invention also provides a method for the
early and accurate detection o fetal renal (kidney) dysfunc-
tion, as early as only 15 weeks gestation.
The present methods may also potentially be used to
monitor for graft-versus-host disease in bone marrow trans-
plants, again by measuring FSC in a biological fluid, most
particularly, serum.
The present methods may be employed for monitoring
renal diseases, particularly renal complications from urinary
tract infection, including localized infection of the upper
(pyelonephritis) and lowerurinary tract (cystitis), interstitial
nephritis, as well as congenital renal dysfunction in utero
(through the measurement of FSC and amniotic fluid)
employing secretory component as the indicating molecule.
The present methods mayalso be used for detecting epithe-
lial injury of other mucosal surfaces, such as that of the
bronchial tubes (for detecting bronchitis) and the extent of
lung injury (such asin cystic fibrosis) by quantifying secre-
tory components in the serum or bronchial secretions.
The effective methods for monitoring the various condi-
tions described herein are also employed in the description
of a diagnostic kit which may be used for monitoring any of
the above conditions, particularly for screening transplant
recipients on a routine basis. Such constitutes a method
superior to organ biopsy, which is currently considered the
most definitive test available for the purpose of monitoring
renal (kidney) rejection.
In a most preferred embodiment of the kit, for the
detection of graft rejection in an animal, the kit comprises a
carrier means adapted to receive at least one multiwell assay
plate andat least three container means. The multiwell assay
plate most preferably is coated with a polymeric immuno-
globulin isolated from a human or other animal biological
sample. The first container means most preferably comprises
free secretory component. The second container means most
preferably comprises an antibody to which an enzyme has
been conjugated and having binding affinity specific for
secretory component polymeric Ig complex. The third con-
tainer means most preferably comprises a colorimetric sub-
strate for the conjugated enzyme.
The antibody is most preferably a monoclonal antibody
6Gi1. Additionally, with regard to the most particularly
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preferred embodimentsof the invention, the receptorligand
detection reagent is an anti-secretory component antibody
bound to an enzyme. By way of example,the antibodies are
bound to the enzyme horseradish peroxidase.
In a most preferred embodiment, the kit further includes
a fourth container means comprising a diluent suitable for
diluting a biological sample, an antibody or FSC. Such a
diluent by way of example, is phosphate buffered saline. A
fifth container means comprising a enzyme reaction buffer
may also be included. By way of example, such an enzyme
reaction buffer is could be a citrate buffer, particularly where
the conjugated enzymeis horseradish peroxidase.
The described kit may also include a printed insert sheet
with instructions for use of the kit in measuring the free
secretory component concentration in an animal biological
sample.
The following examples are presented only to describe
preferred embodimentsandutilities of the present invention
andto satisfy best mode requirements. The examplesare not
intended to limit the scope of the present invention unless
specifically indicated otherwise in the claims appended
hereto. Thus, it is to be understood that other utilities and
advantages and modifications of the specially described
aspects of the present invention are embraced within the
scope of the following claims.
Examples presented herein include:
Example 1—-Assay for Free Secretory Component in a
Biological Sample
Example 2—Free Secretory Component in Renal Trans-
plant Patients
Example 3—Secretory Component in Amniotic Fluid to
Detect Fetal Kidney Dysfunction
Prophetic Proposed Comparative Study of Human Sub-
ject Study
Example 4—of FSC Relevant to Age, Sex, Pathological
Condition and Transplant Status
Prophetic Proposed Diagnostic Kit for the Measurement
of
Example 5—Free Secretory Component
Example 1
Assay for Free Secretory Component in a
Biological Sample
The present example is provided to demonstrate the
ELISAassay as modified and adapted by the inventors for
the specific measurement of FSC in a biological sample,
particularly for measurement of FSC in a voided urine
sample obtained from a human. The object was to develop
a simple, rapid and specific immunoassay for quantifying
FSCin a representative biological fluid such as urine, which
establishes the utility of employing the presently described
method for measuring FSCin other biological samples, such
as bile, bronchial secretions, amniotic fluid, and blood
(particularly blood components such as serum).
The modified ELISA assay described herein will be used
to standardize the urine baseline levels of FSC from human
urine samples, and to quantify FSC concentrations in urine
obtained from renal allograft recipients, most of whom may
have been suspected of having had an episode ofallograft
rejection. A second object of the present example is to
demonstrate a form of the modified ELISA assay which
could be used in commercial application for measuring
5,484,707
15
urinary FSC concentrationsin the private clinical laboratory
or hospital for early detection of renal transplantrejection.
The assay for measuring FSC in a biological fluid (which
also may contain secretory component bound to immuno-
globulins, such as secretory IgA and IgM) used in the
present invention is a modified sandwich-type enzyme
linked immunosorbent assay (ELISA) specifically adapted
for the purpose of measuring FSC. The modified ELISA
included the steps outlined in Table 1.
In this quantitative ELISA, free SC is captured on dimeric
IgA coated wells. A major advantage of this assay system is
its binding specificity for free SC, since SC already bound
to IgA (sIgA) will not bind to dimeric IgA’. Using free SC
purified from human milk as a standard°>this assay can be
used to quantify the free SC contentof virtually any biologic
fluid.
The FSC immunoassay, accordingto the present example,
may also be used to determine if a spot urine collection (in
which FSC quantification results are normalized to the
concentration of creatinine in the sample), can substitute for
a timed urine sample in quantifying the FSC excretionrate.
Adult urine samples were collected randomly from normal
(i.e., non-transplant recipient) donors. Briefly, the modified
ELISAprotocol developed in the present. example, as used
in preferred embodiments of the present invention, is
described as follows:
ELISA Procedure for Clinical Patient Samples
Coating the Plates
1. Coat round bottom 96-well microliter plate with 150
pl/well IgM diluted to 3 pg/ml in 0.125M (pH 8.2) borate
saline buffer. Coat all wells except row “A”, this row isleft
as an O-coat control In row “A”,fill wells with 150 pl/well
borate saline buffer.
2, Cover the plate with sealing tape and incubatethe plate
in a 37° C. dry incubator overnight.
3. After the incubation periodthe plate, still sealed with
tape, can be stored at 4° C. and used in the presently
described assay for up to 6 months.
Addition of Free Secretory Component
1. Wash plate 8 times with Tween-saline to remove any
non-boundantigen. Blot the plate on aL paper towel, check-
ing to be sure all liquid and air bubbles are removed.
2. Fill all 96 wells with 150 ul Tween phosphate buffered
saline (0.05M,pH 7.1). Each sample (e.g., urine sample) is
assayed in duplicate and in “coated” wells and added to at
least one “uncoated” control well. This is done as a back-
ground check. In eachtest well, 50 ul of sample is added to
the 150 ul of buffer. The solution in each well is mixed by
pipetting up and down 7-8 times without causing air
bubbles. Draw out 50 pl from the control well and discard
so that this well will not contain a 1:4 dilution. In the row
B wells, add 50 pl of sample. Mix well, draw out 50 ul, and
transfer to row C. Mix the contents of these wells thor-
oughly, and transfer 50 pl to the next row. Continue the
above through row G,at which point 50 ul will be removed
and discarded. Row H contains only Tween PBS;these wells
are zero sample controls. The final volume of each well is
150 jl. FSC standardis diluted to a concentration of 2 ul/ml
with Tween PBS andtreated exactly as the samples.
3. Place a plastic lid over the plate and incubate at room
temperature, with shaking, for 4 hours.
Addition of Antibody (Conjugate)
1. Wash plate 8 times with Tweensaline.
2. Dilute conjugate in Tween PBS. Prepare rabbit anti-
human secretory component horseradish peroxidase (conju-
gate) at a 1:200 dilution.
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3. Add 150 ul of diluted conjugate to all 96 wells.
4. Incubate at room temperature, with shaking, for 4
hours.
Enzyme Reaction
1. Wash plate about 8 times with Tween saline.
2. For a horseradish peroxidase conjugate—Mix O-phe-
nylenediamine dihydrochloride with citrate buffer (0.05M,
pH 4.9) (0.2 mg OPD for every 1 ml ofcitrate buffer.) Add
3% Hydrogen Peroxide (50 pl H,O, for every 20 ml citrate
buffer). Add 150 pl of above substrate to all 96 wells,
starting with row A and working downto row H.Time the
reaction and watch for a color change (from clear to bright
yellow). Stop the reaction by adding 50 ul of SN H,SO,to
all 96 wells in the same sequence as addition of substrate.
3. Read plates on Dynatech ELISA reader. Be sure the
wavelengths on the reader are set for the selected “conju-
gate” used in the assay (for example, set at wavelength 490
nm when horseradish peroxidase is used as the conjugate).
4. Graphdata on 4 cycle semi-log paper Primary Antibody
Dilution vs. OD per 100 minutes.
5. Calculate the concentrations of free SC in samples from
the absorbance curve of sample and the standard. The free
SC concentrations are reported as the average ofthe dupli-
cate determinations.
TABLE1
Modified ELISA for Quantifying
Free Secretory Component.
 
Plate or Surface Surface of a plastic vessel or
wells of a polystyrene micro-
plgA titer plate are coated with
or human polymeric IgA, or IZM
IeM or monoclonal anti-
body 6G11 specific for FSC
i>IgA Unbound IgA removed by
washing
+FSC Add source ofFSC
|
| Add biological sample (e.g.
urine) or purified
| secretory componentstandard
plgA-FSC andallow to bindto the poly-
meric IgM or IgA coat(4 hr.
incubation at 25° C.).
Unbound material removed by
washing
Add detecting antibody ->(
+ Anti-SC-Enzyme Polyclonal or monoclonal anti-
bodies against secretory
componentof sIgA, conjugated
with horseradish peroxidase,
is added (4 hr. incubation
period at 25° C.
plgA-FSC-
Anti-SC-Enzyme
Unboundconjugate is removed
by washing with 0.05% Tween
phosphate bufferedsaline~
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TABLE 1-continued
Modified ELISA for Quantifying
Free Secretory Component.
 
+ substrateV
plgA FSC Anti-SC-Enzyme
Add colorimetric substrate (e.g.
0.2 mg/ml O-phenylenediamine
dihydrochloride in citrate buffer)
Stop reaction with sulfuric acid
The enzyme boundto the
tube is quantified using
a colorimetric substrate
and spectrophotometry
Colored product
Read plates under ELISA
reader @ 490 nM wavelength
 
Creatinine is quantified from an aliquot of the same urine
sample by standard techniques. The results are expressed as
micrograms (ug) of FSC per milligram (mg) of creatinine.
Using the foregoing described modified ELISA, the FSC/
creatinine ratio for nonpregnant adults was determined to be
approximately 1.04 ug FSC/mg creatinine (Range
0.19-3.38). Two pregnant adults demonstrated a mean free
secretory component concentration approximately three
times the amount of a non-pregnant adult.
The mean FSC urine concentration of the renal transplant
patient was 18 ug secretory component/mg of creatinine
(Range 0-137 mg). Twelve of the 20 patients had levels
above the range of normal subjects on at least one of their
tests.
Table 3 presents average FSC concentrations character-
istic of different biological samples, such as adult urine
(1.18+0.91), adult parotid fluid (6.6144), adult bile
(7.49+9.8) and human milk (19904531).
TABLE 2
Concentrations of free SC in
amniotic fluid compared with that of other secretions
 
Free SC Content (ug/ml)
Secretion Number of Samples Mean S.D.
Amniotic fluid 25 7A5 7.04
Neonatal Urine 7 6.79 3.45
Adult Urine 13 1.18 0.91
Adult Parotid Fluid 9 6.61 4.00
Adult Bile 5 7.49 9.80
Adult Milk 5 1990 531
 
The term “modified” is used in the presently described
protocol, a human immunoglobulin (IgM or polymeric IgA)
is used as the first “capture” phase of the assay. This binds
FSC as a ligand receptor complex, not as an antibody. In
most ELISA’s the “capture”reagent is an animal antibody to
the analyte (analyte is FSC, in this case).
An antibody having binding affinity specific for FSC may
be substituted for polymeric immunoglobulin as the capture
reagent in the practice of the present assay for measuring
FSC. An antibody most preferred in the practice of the
present invention is the monoclonal antibody, 6G11, which
is highly specific for FSC. This antibody most preferably
may be added to a microliter well dilute to an appropriate
concentration in a buffer, such as 10 mM phosphate buffered
(or borate buffered) saline, pH 7.4. The 6G11-coated wells
are then employed to measure FSC concentrate in biological
samples from non-organ transplant and organ t patients.
Mostpreferably, human serum products are to be used in
the practice the present assay. Various reagents known to
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stabilize antibodies absorbed to a solid phase may also be
used in the practice of the presently described assay in order
to allow the plates to be stored dry. The stabilizing reagents
which are planned for use in the described assay include
various concentrationsof sugars, gelatins, or buffers, such as
0.1M sodium phosphate, pH 7.4.
A secondary (monoclonal or polyclonal) antibody (i.e., a
receptor ligand detecting reagent), specific for sigA, SC and
FSC is used in the practice of the present invention. These
secondary antibodies are characterized by their ability to
bind to epitopes .distinct from the ones recognized by
polymeric IgA or monoclonal 6G11. Most preferably, the
antibodies employed in the described assay are purified by
affinity chromatography on staphylococcal protein A and
conjugated to horseradish peroxidase by a modification of
the Nakaneet al. procedure*'.
The presently described ELISA for FSCis relatively free
of cross-reactivity to sIgA, IgG, IgM, cyclosporin and
antibiotics. Therefore, these substances are expected by the
inventors to have relatively no effect on the assay value of
the sample FSC concentration obtained according to the
presently described method. The sensitivity of the described
ELISAassay is currently about 10 ng/ml FSC for detecting
FSC in a biological sample of urine.
The following table presents control values for FSC urine
samples as obtained from a population of 10 normal (non-
allograft) human subjects using the modified ELISA assay
described herein. Creatinine measurements were obtained
according the procedure described by Jaffe*?.
TABLE 3
Rodney’s Normal Values for FSC
 
FSC Creat FSC/Creat
Subjects ug/ml mg/ml ug/mg
1 0.089 0.56 0.159
2 0.285 1.06 0.269
3 0.330 1.43 0.231
4 0.135 0.67 0.201
5 0.120 0.59 0.203
6 0.195 1.24 0.157
7 0.180 1.61 0.112
8g 0.750 2.87 0.261
9 0.285 1.38 0.207
10 0.690 2.44 0.283
Mean. 0.306 1.385 0.208
STD 0.220 0.729 0.052
CN. 0.720 0.527 0.249
 
The data of Table 3 presents concentrations of FSC and
FSC/creatinine measured by the inventors employing the
modified ELISA protoco! described at Table 1. The mean
FSC concentration observed was 0.306 yg/ml+0.220. Cor-
rected for creatinine concentration (mg/ml), the sample
readings yielded a mean of 0.208:40.052 ug FSC/mg crea-
tinine.
Example 2
Free Secretory Component in Renal Transplant
Patients
The present example provides the range of FSC level
observed in adult renal transplant patient urine samples.
These results support the correlation between elevated uri-
nary FSC excretion and the incidence of allograft (kidney)
rejection, and are submitted to demonstrate the utility of
employing patient FSC concentration in a method for iden-
tifying graft rejection in an animal.
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In this study, 20 consecutive patients admitted to a medi-
cal transplant unit for suspected renal allograft rejection or
other complaints were tested each weekday morning for
FSC excretion. Normal urine was collected from laboratory
personnel (no history of organ transplant) to provide control
values. FSC was quantified in the fresh urine samples using
the modified sandwich-type ELISA developed in the inven-
tors’ laboratory (see Table 1, Example 1). The results were
normalized for urinary creatinine concentration. The histo-
logic diagnosis of 11 of these patients was established by an
independent (blinded) review of the renal biopsies by the
inventors. The data obtained from the 11 patients whose
diagnosis was established by renal biopsy in this study is
included in Table 4.
TABLE 4
 
Urinary Free Secretory Componentin Renal Transplant Patients
Patient
Num- FSC Creatinine Biopsy
ber ug/ml mg/ml FSC/Creat Results
Patients with biopsy evidence of renal allograft rejection:
 
1 0.8-18.0*  —0.19-0.33 0-94.9 Severe Rejection
7 9.3-36.8 0.3-0.99 15.6-49.1 Mild Rejection
9 56.4 0.41 137.6 A & C Rejection
14 2.4-10.8 1.4-1.9 1.7-5.7 Mild Rejection
16 5.3 0.46 11.5 Chronic Rejection
2 1.1-2.5 0.84-0.87 1.3-3.0 Chronic Rejection
Patients with no evidence of rejection on biopsy:
4 6.2-13.6 0.42-1.4 4.5-26.2 CSAToxicity
3 0.7 0.64 1.1 ATIN
5 0.0 0.41 0.0 ATN
11 0.0-2.5 0.08-0.27 0.0-16.0 Throm
Microangiopathy
13 0.0 0.32-0.4 0.0 Chronic CSA
Toxicity
Normal adult values (N = 15)
Mean 1.16 1.03 1.09
Std 1.4 0.63 0.79
Dev
Range 0.21-3.12 0.32-2.45 0.19-3.38
 
*Range of values during a single hospitalization (1-9 per patient). In many
cases immunosuppressive medications were altered during the hospitaliza-
tion.A&C=acute & chronic; ATN = acute tubular necrosis; Throm = thrombotic;
CSA = cyclosporin A.
The FSC concentration and FSC/creatinine ratio in the
transplant recipients were frequently much higher than those
in the normal subjects. More specifically, concentrations of
urinary FSC were generally higher in the patients with
biopsy evidence of allograft rejection, compared to trans-
plant patients with no evidence of rejection on biopsy. One
out of the five patients whose renal biopsy did not show
rejection did have elevated levels of FSC (Patient No.
4—Table 4). However, this patient was judged to be having
graft rejection on the basis of clinical findings and routine
laboratory tests, suggesting that the biopsy might have been
done before the pathologic findings became diagnostic of
rejection. In contrast, all of the patients who had renal biopsy
evidence of organ (kidney) rejection also had increased
urine FSC concentration detectable at some point during
their hospitalization.
The FSC data on patients who did not have renal biopsies
seemed to follow the same general pattern (i.e., generally
lower FSC/creatinine ratios).
Preliminary correlations of the urinary FSC values with
clinical and laboratory indicators of renal graft rejection for
the entire group (with an without biopsy) revealed that of 8
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patients who the clinician thought to be undergoing renal
allograft rejection, 7 had a FSC/creatinine ratio of greater
than 5 pg FSC/mg of creatinine in at least one sampling
specimen.Of the eight patients who were not thought to have
allograft rejection or infection, only 2 had a level of above
5 pg FSC/mgcreatinine (25%) false positive rate. One renal
transplant recipient who was admitted for control of his
hyperiension (a recognized sign of renal allograft rejection)
also had high FSC levels in all of his urine samples col-
lected.
The mean FSC level in the urine of the whole group of
renal transplant patients (admitted because of suspected
rejection) was 18 g FSC/mg ofcreatinine (Range 0-137
pg/mg). Twelve (12) of the twenty (20) patients had levels
above the range of the determined “normal” subjects in at
least one of the sample specimens collected. Four (4)
patients had FSC levels below detectability in at least one of
the sample specimens collected, while six demonstrated
FSC levels consistently within the range of the normal
subjects.
These results demonstrate that the level of FSC in a
patient sample is a reliable indicator of kidney injury caused
by allograft rejection. The presently disclosed methods
therefore provide a useful clinical tool for screening organ
transplant recipients to detect early organ transplant rejec-
tion. Additionally, monitoring for elevated FSC levels in
urine could be used to alert the physician to the need for
further testing, and possibly treatment of the transplant
patient to prevent and/or halt an ongoing organ rejection
episode.
Example 3
Secretory Component Amniotic Fluid to Detect
Fetal Kidney Dysfunction
The present example is provided to demonstratetheutility
of the claimed invention for the detection of kidney dys-
function in a fetus, and the diagnostic value of measuring
FSC in amniotic fluid for identifying fetal renal dysfunction.
The inventors propose that these methods will have utility
for the detection of Potter’s syndrome, a condition charac-
terized by abnormal fetal kidney development. According to
the techniques disclosed for the present invention, condi-
tions such as Potter’s syndrome may be monitored and
detected in the unborn child by obtaining a sample of the
amniotic fluid which surroundsthe fetus. This amniotic fluid
sample may then be measuredfor free secretory component
(FSC) using the modified ELISA methods described herein.
The vast majority of AmF volumeis derived from fetal
urine, especially during the later half of pregnancy.*° Since
adult urine is known to contain low levels of sIgA,?’ a
potential source for the free SC was proposed by the present
inventors in AMF.
Results presented in the present example indicate that
most of the secretory component (SC) in human amniotic
fluid (AmF) exists in its free form. The inventors also show
that SC concentration in AmF will vary in concentration
directly with the gestational age of the fetus. The free SC is
also shownto migrate at a slightly larger apparent molecular
weight on SDS-PAGE.
Amniotic fluid samples were obtained from pregnant
females according to techniques well knownfor this process
by thoseof skill in the obstetrical medical arts. In the present
example, free SC was quantified in amniotic fluid samples
obtained from term amniocenteses (37-40 weeksgestation)
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(See Table 2 supra) as well as from amniocentesesof earlier
gestational pregnancies.
Effect of gestational age on free SC concentration in AmF.
The concentration of FSC relative to gestational age was
examined. The modified ELISA assay described in Example
1 was employed to measure FSC in the amniotic fluid
samples.
FIG.1 is a scatter plot of the concentrations of free SC in
50 AmF samples collected at various gestational ages. The
concentration of free SC in AmF appears to be directly
related to the gestational ageof the fetus, especially between
26-40 weeksgestational age. While SC concentration varied
in samples of similar gestational ages, substantial quantities
of free SC were found in all samples from pregnancies of
greater than 21 weeks duration, and free SC was detected in
two of the three samples from the earliest stage of gestation
(16 weeks) tested. The concentration of free SC began to rise
steadily after 26 weeks, and at term, free SC levels ranged
from 2~28 pg/ml.
The difficulty associated with obtaining specimens early
in gestation prevents a determination of the exact relation-
ship between free SC and gestational age. However, a simple
linear regression between the concentration of SC and
gestational age between 26 to 40 weeks yielded a line with
a slope of 0.692, a correlation coefficient of 0.374, and a p
value of 0.014 (two tailed T test), indicating that free SC
concentrations in AMF increase with gestational3- age from
between 26 to 40 weeks.
The free SC concentration of AmF samples (38-40
weeks) was compared to that in the first voided urine of
newbom infants and various other secretions (adult urine,
parotid fluid, bile, and milk) in Table 2. These results show
that the free SC concentration inAmF is similar to that found
in neonatal urine, but both are higher than concentrations
found in random adult urine (See Table 2). The concentra-
tion of free SC in AmF was also similar to concentrations
foundin bile and parotid fluid. In contrast, the concentration
of free SC in milk was much higher than in AmF or other
secretions.
In a particularly preferred embodiment of the prenatal
diagnosis aspect of the invention, FSC is to be measured in
amniotic fluid obtained from pregnant females wherein the
fetus is of at least 21 weeks gestation. A concentration of
FSC from a pregnant animal which is significantly lower
than a control FSC concentration in AmF obtained from a
similar gestational pregnancy would indicate a fetus at risk
of having renal dysfunction.
Prophetic Example 5
Proposed Comparative FBC Study of Human
Subjects Relative to Age, Sex, Pathological
Condition and Transplant Status
The present prophetic example is provided to outline a
proposed comparative study to determine a baseline or
“normal” secretory component concentration level from
patients in various physiological states (young, old, trans-
planted w/disease, transplanted w/o disease, pregnant, non-
pregnant) as well as between the sexes (male vs. female).
Evaluation of relative elevated or decreased free SC levels
in a transplant patient or pregnant female patient may then
be compared with the distribution of FSC concentrations
defined for these populations. Additionally, the proposed
study will provide data which may aid in the development of
therapeutic products for treating individual kidney trans-
plant patients.
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A numberofdifferent subject populations will be studied
in the proposed project. In each case, the subject will be
asked to
provide single or multiple voided urine samples. The
populations proposed for study are listed below:
 
Health Status Number Age Range Sex Ethnic
a. Normal adults and 30 4-90 yrs M&F Mixed
children
b. Pregnant females 10 18-40 yrs F Mixed
c, Acute 10 490 yrs M&F Mixed
pyelonephritis
d. Bacterial pneumonia 10 490 yrs M&F Mixed
e. Active rheumatic
disease 10 4-90 ys M&F Mixed
f. Kidney transplant 20 4-90 ys M&F Mixed
recipients with no
signs of rejection
g. Patients other than 10 14-90 ys M&F Mixed
transplant
recipients receiving
cyclosporin
 
The inclusion and exclusion criteria to be applied in the
present study are solely related to the subject’s health status
and the particular patients ability to reliably provide a urine
sample. Where the patient population being tested are
females, the womenwill be tested during each phaseoftheir
menstrual cycle.
Pregnant females will be considered separately. This
group of females will be considered separately because
evidence in the literature that female sex hormones.(i.e.,
estrogen) alter the production of SC**.
Results from this proposed study will provide estimates of
the means and confidence limits for FSC concentration for
eachofthe populations of: normal adult males; normal adult
females (non-pregnant); pregnant females; children; trans-
plant recipients not demonstrating an organ-rejection epi-
sode; patients with kidney infection or other infections and
generalized inflammation; and patients receiving
cyclosporin independent of kidney transplantation. These
baselline reference population FSC concentrations will then
be employed for identifying allograft rejection in a patient
using the reference population most similar to the test
subject animal.
Prophetic Example 6
Proposed Diagnostic Kit for the Measurement of
Free Secretory Component
The present example is provided to demonstrate a pre-
ferred embodiment contemplated by the inventors for a
diagnostic kit to be used to monitor patients for organ
transplant rejection. The kit is also expected to have diag-
nostic utility for monitoring and detecting other forms of
kidney inflammation in the patient’s own kidney. In addition
the proposed kit may be used for detecting fetal renal
dysfunction in a pregnant animal, such as fetal Potter’s
syndrome, using, for example, an amniotic fluid sample.
The kit comprises a carrier means adapted to receive at
least one multiwell assay plate and at least three container
means in close confinement therewith; at least one multiwell
assay plate;a first container means comprising free secretory
component; a second container means comprising an
enzyme conjugated antibody capable of binding to the
receptor (secretory component) ligand (polymeric Ig) com-
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plex; and a third container means containing a colorimetric
substrate for the enzyme.
The kit may also include a fourth container means com-
prising an appropriate diluent for the antibody, FSC or
sample, such as for example phosphate buffered saline. The
kit may also further include fifth container mean containing
an enzyme reaction buffer. By way of example, an enzyme
reaction buffer is citrate bugger, particularly where the
conjugated enzyme is horseradish peroxide.
It is contemplated that the described kit will be widely
applicable for use in hospitals and private clinical laborato-
ries, for the detection of either single graft rejections or
multi-transplant organ rejection (i.e., where the patient has
had multiple organ transplants) episodes in patients.
The carrier means will] most preferably be constructed of
a durable plastic material.
The presently described diagnostic kits may also option-
ally comprise a multiwell microliter plate which is pre-
coated with an appropriate concentration of a monoclonal
antibody to FSC, and a pamphlet of written instructions for
use of the kit. In a most preferred embodiment of the
described kit, the antibody is the monoclonal antibody 6G11.
The antibody and the hybridoma which produces the mono-
clonal antibody is maintained in the inventors laboratory at
the following address:
Dr. Randall Goldblum
Department of Pediatrics
The University of Texas Medical Branch, Galveston, Tex.
Mostpreferably, the ligand capture reagent is a polymeric
immunoglobulin, such as plgA or IgM.
A suitable urine or urine-like solution will be developed
to provide acceptable stability of FSC standards to be used
where the test sample is a voided human urine sample. Free
secretory component (FSC) purified from human breast milk
will be used to prepare standards in a matrix that approxi-
matesthat of urine. If FSC is not sufficiently stable in urine
or a urine-like solution, stabilizers and bulking agents, such
as gelatin, etc., may be added to the solution to enhance
stability of the FSC in solution.
Stabilizers and bulking agents, such as gelatin, etc., may
be added to the solution to enhance thestability of the FSC
in solution, such as in a solution of urine.
The following references, in pertinent part, are specifi-
cally incorporated herein by reference for the purposes
indicated herein.
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Whatis claimed is:
1. A methodfor inhibiting a kidney transplant rejection in
an animal with a kidney transplant comprising:
obtaining a urine sample from the animal at periodic
intervals after the kidney is transplanted;
measuring FSC concentrations in each urine sample of the
animal to provide FSC test concentrations;
determining an FSC control urine concentration;
identifying an elevated FSC test concentration in a test
sample having an FSC concentration greater than the
FSC control urine concentration as determined by an
immunological method;
employing said elevated FSC test, concentration as an aid
in identifying an animal undergoing a kidney rejection
episode; and
treating the animal undergoing a kidney rejection episode
with a regimen of immunosuppressive agents to inhibit
kidney rejection in the animal.
2. A method for aiding in identifying a renal allograft
rejection episode in a kidney transplant patient comprising:
obtaining a urine sample from the transplant patient;
determining the concentration of FSC in the patient urine
sample to provide an FSC test concentration;
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determining an FSC urine control concentration;
comparing the FSC test concentration to the FSC control
concentration; and
identifying a renal allograft rejection episode in the kid-
ney transplant patient when an FSC test concentration
is greater than the FSC control concentration as deter-
mined by an immunological method.
3. The method of claim 1 or 2 wherein the FSC concen-
tration of a urine test sample is determined by an enzyme
linked immunosorbentassay.
4. The method of claim 1 or 2 wherein the FSC control
concentration is about 1 pg/ml as determined by an immu-
nological method.
5. The method of claim 1 or 2 wherein the FSC control
concentration and the FSC test concentration are normalized
as against a creatinine concentration of the biological
sample.
6. A method for aiding in distinguishing renal allograft
rejection injury from renal non-allograft injury in a kidney
transplant patient comprising:
obiaining a urine sample from the kidney transplant
patient with a form of kidney injury;
determining a FSC concentration in the patient urine
sample to provide an FSC test concentration;
determining an FSC control concentration from urine
sample obtained from non-kidney transplant patients;
and
comparing the FSC test concentration to the FSC control
concentration as determined by an immunological
method;
wherein an FSC test concentration greater than the FSC
control concentration indicates s renal allograft rejection
injury in the kidney transplant patient and wherein an FSC
test concentration the same as or less than the FSC control
concentration indicates renal non-allograft injury.
7. The method of claim 6 wherein a form of kidney injury
is identified in a kidney transplant patient having an elevated
level of a marker selected from the group consisting of
gamma glutamyl trans-peptidase; N-acetyl-B-D-glu-
cosaminidase; adenosine deaminase-binding protein;
complement component; and lysozyme.
8. The method of claim 6 wherein the FSC test concen-
tration and the FSC control concentration are normalized
against a creatinine concentration of the urine sample.
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9. A method for identifying renal inflammation in an
animal not having a kidney transplant comprising:
obtaining a urine sample from the animal;
determining the FSC concentration in the animal urine
sample by an immunological method to provide an FSC
test concentration;
determining an FSC control concentration by an immu-
nological method; and
comparing the FSC test concentration to the FSC control
concentration;
wherein an FSC test concentration greater than the FSC
control concentration indicates renal inflammation in the
animal.
10. The method of claim 9 wherein the animal is a human.
11. The method of claim 9 wherein renal inflammation is
renal infection or renal tubular inflammatory injury.
12, Akit for use in the identification of an ongoing kidney
graft rejection in an organ in an animal comprising:
a carrier means adapted to receive at least one multi-well
assay plate and at least three container means;
at least one multi-well assay plate coated with a binding
member polymeric IgA or IqM capable of specifically
binding free secretory component;
a first container means comprising FSC;
a second container means comprising a detecting reagent
of an enzyme conjugated-antibody, said antibody hav-
ing binding affinity specific for secretory component-
polymeric immunoglobulin complex; and
a third container means comprising a colorimetric sub-
strate for the enzyme.
13. The kit of claim 12 wherein the detecting reagent is an
anti-secretory component antibody bound to an enzyme.
14. The kit of claim 13 wherein the FSC is isolated from
human milk.
15. The kit of claim 12 which further includes a fourth
container means having a diluent suitable for diluting a
biological sample, the detecting reagent or FSC.
16. The kit of claim 15 which further includes a fifth
container means having an enzyme reaction buffer.
17. The kit of claim 16 wherein the enzyme reaction
buffer is a citrate buffer where the enzyme is a conjugated
enzyme horseradish peroxidase.
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